Selenium speciation studies in cancer patients to evaluate the responses of biomarkers of selenium status to different selenium compounds
© 2024. The Author(s)..
This work presents the first systematic comparison of selenium (Se) speciation in plasma from cancer patients treated orally with three Se compounds (sodium selenite, SS; L-selenomethionine, SeMet; or Se-methylselenocysteine, MSC) at 400 µg/day for 28 days. The primary goal was to investigate how these chemical forms of Se affect the plasma Se distribution, aiming to identify the most effective Se compound for optimal selenoprotein expression. This was achieved using methodology based on HPLC-ICP-MS after sample preparation/fractionation approaches. Measurements of total Se in plasma samples collected before and after 4 weeks of treatment showed that median total Se levels increased significantly from 89.6 to 126.4 µg kg-1 Se (p < 0.001), particularly when SeMet was administered (190.4 µg kg-1 Se). Speciation studies showed that the most critical differences between treated and baseline samples were seen for selenoprotein P (SELENOP) and selenoalbumin after administration with MSC (p = 5.8 × 10-4) and SeMet (p = 6.8 × 10-5), respectively. Notably, selenosugar-1 was detected in all low-molecular-weight plasma fractions following treatment, particularly with MSC. Two different chromatographic approaches and spiking experiments demonstrated that about 45% of that increase in SELENOP levels (to ~ 8.8 mg L-1) with SeMet is likely due to the non-specific incorporation of SeMet into the SELENOP affinity fraction. To the authors' knowledge, this has not been reported to date. Therefore, SELENOP is probably part of both the regulated (55%) and non-regulated (45%) Se pools after SeMet administration, whereas SS and MSC mainly contribute to the regulated one.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:416 |
|---|---|
| Enthalten in: |
Analytical and bioanalytical chemistry - 416(2024), 11 vom: 29. Apr., Seite 2835-2848 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Del Castillo Busto, M Estela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
964MRK2PEL |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00216-024-05141-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367771950 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367771950 | ||
| 003 | DE-627 | ||
| 005 | 20240425232755.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00216-024-05141-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM367771950 | ||
| 035 | |a (NLM)38286852 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Del Castillo Busto, M Estela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Selenium speciation studies in cancer patients to evaluate the responses of biomarkers of selenium status to different selenium compounds |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a This work presents the first systematic comparison of selenium (Se) speciation in plasma from cancer patients treated orally with three Se compounds (sodium selenite, SS; L-selenomethionine, SeMet; or Se-methylselenocysteine, MSC) at 400 µg/day for 28 days. The primary goal was to investigate how these chemical forms of Se affect the plasma Se distribution, aiming to identify the most effective Se compound for optimal selenoprotein expression. This was achieved using methodology based on HPLC-ICP-MS after sample preparation/fractionation approaches. Measurements of total Se in plasma samples collected before and after 4 weeks of treatment showed that median total Se levels increased significantly from 89.6 to 126.4 µg kg-1 Se (p < 0.001), particularly when SeMet was administered (190.4 µg kg-1 Se). Speciation studies showed that the most critical differences between treated and baseline samples were seen for selenoprotein P (SELENOP) and selenoalbumin after administration with MSC (p = 5.8 × 10-4) and SeMet (p = 6.8 × 10-5), respectively. Notably, selenosugar-1 was detected in all low-molecular-weight plasma fractions following treatment, particularly with MSC. Two different chromatographic approaches and spiking experiments demonstrated that about 45% of that increase in SELENOP levels (to ~ 8.8 mg L-1) with SeMet is likely due to the non-specific incorporation of SeMet into the SELENOP affinity fraction. To the authors' knowledge, this has not been reported to date. Therefore, SELENOP is probably part of both the regulated (55%) and non-regulated (45%) Se pools after SeMet administration, whereas SS and MSC mainly contribute to the regulated one | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a ICP-MS | |
| 650 | 4 | |a Se-methylselenocysteine | |
| 650 | 4 | |a Selenium speciation | |
| 650 | 4 | |a Seleno-L-methionine | |
| 650 | 4 | |a Sodium selenite | |
| 650 | 7 | |a Selenium Compounds |2 NLM | |
| 650 | 7 | |a Selenium |2 NLM | |
| 650 | 7 | |a H6241UJ22B |2 NLM | |
| 650 | 7 | |a Selenomethionine |2 NLM | |
| 650 | 7 | |a 964MRK2PEL |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Ward-Deitrich, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Stephen O |e verfasserin |4 aut | |
| 700 | 1 | |a Rayman, Margaret P |e verfasserin |4 aut | |
| 700 | 1 | |a Jameson, Michael B |e verfasserin |4 aut | |
| 700 | 1 | |a Goenaga-Infante, Heidi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Analytical and bioanalytical chemistry |d 1995 |g 416(2024), 11 vom: 29. Apr., Seite 2835-2848 |w (DE-627)NLM118176722 |x 1618-2650 |7 nnns |
| 773 | 1 | 8 | |g volume:416 |g year:2024 |g number:11 |g day:29 |g month:04 |g pages:2835-2848 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00216-024-05141-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 416 |j 2024 |e 11 |b 29 |c 04 |h 2835-2848 | ||